Omnicell Inc. reported total revenues of USD 314 million for the fourth quarter (Q4) of 2025, reflecting a 2 percent increase compared to the same period in the previous year. For the full year (FY) ended December 31, 2025, total revenues reached USD 1.19 billion, up 7 percent year-over-year. The company reported a GAAP net loss of USD 2 million, or USD 0.05 per diluted share, for Q4 2025. Cash and cash equivalents as of December 31, 2025, stood at USD 197 million, with total debt (net of unamortized debt issuance costs) at USD 168 million, and total assets at USD 1.97 billion. Cash flows provided by operating activities totaled USD 30 million in Q4 2025. During the period, Omnicell introduced the Titan XT, a new enterprise version of its automated dispensing systems, designed to enhance and unify automation and medication management intelligence. The company maintains USD 350 million of available credit under its revolving credit facility with no outstanding balance. Management highlighted strength in technical service offerings, software-as-a-service and expert services, as well as consumables revenues, as key drivers of growth in both the quarter and the fiscal year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omnicell Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000926326-26-000003), on February 05, 2026, and is solely responsible for the information contained therein.